QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 adagene-announced-new-adg126-clinical-data-from-from-ongoing-phase-1b2-trial-of-safebody-plus-keytruda-combo-
-presented-at-the-esmo-congress

Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for...

 adagene-presents-new-phase-1b2-data-on-adg126-and-keytruda-combination-therapy-for-metastatic-crc-at-esmo-congress

Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based th...

 adagene-h1-eps-026
Adagene H1 EPS $(0.26)
07/25/2024 20:41:52

Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.26) per share.

 hc-wainwright--co-reiterates-buy-on-adagene-maintains-5-price-target

HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $5 price target.

 hc-wainwright--co-reiterates-buy-on-adagene-maintains-5-price-target

HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $5 price target.

Core News & Articles

Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab antic...

 why-transcode-therapeutics-shares-are-trading-lower-by-over-24-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,...

 why-airspan-networks-shares-are-trading-higher-by-over-380-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announ...

 why-is-cancer-focused-adagene-stock-plummeting-today

Adagene presents results at ASCO 2024 Gastrointestinal Cancers Symposium. ADG126, combined with Merck's Keytruda, shows lim...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION